Predicting death from HIV/AIDS: a case-control study from Florida public HIV/AIDS clinics.
BACKGROUND
After markedly decreasing for 3 years, HIV/AIDS mortality declined only slightly in 1999.


METHODS
The authors conducted a case-control study in four Florida urban public health HIV clinics to evaluate modifiable factors associated with HIV/AIDS mortality in a non-research setting. Structured chart review was conducted for 120 case-patients who died in 1999 and for 240 randomly selected control-patients. Risk factors associated with death in univariate analysis were entered into three conceptually related, matched logistic regression models.


RESULTS
In the final multivariate model, homelessness (adjusted odds ratio [AOR], 9.98; 95% confidence interval [CI], 2.34-42.5), Medicaid insurance (AOR, 3.10; 95% CI, 1.43-6.74), having a documented adherence problem (AOR, 3.50; 95% CI, 1.64-7.47), injection drug use (AOR, 2.46; 95% CI, 1.11-5.43), non-specific liver failure (AOR, 76.9; 95% CI, 6.79-870.9), interrupted highly active antiretroviral therapy (HAART) secondary to side effects (AOR, 4.00; 95% CI, 1.46-10.9), and not receiving HAART (AOR, 2.62; 95% CI, 1.03-6.68) were independent predictors of mortality.


CONCLUSIONS
In addition to medical and clinical indicators, several sociobehavioral-demographic factors remained important throughout the multivariate analysis. Improvement in care should include a focus on social circumstances of infected people. Special attention to the homeless, those with adherence problems, and those with liver disease is clearly indicated.
Lieb
Spencer
S
Florida Department of Health, Tallahassee 32399-1715, USA. spencer_lieb@doh.state.fl.us
Brooks
Robert G
RG
Hopkins
Richard S
RS
Thompson
Dan
D
Crockett
Landis K
LK
Liberti
Thomas
T
Jani
Asim A
AA
Nadler
Jeffrey P
JP
Virkud
Vikas M
VM
West
Karen C
KC
McLaughlin
Gayle
G
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000276:immunology / Q000401:mortality*; D000293:Adolescent; D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D016022:Case-Control Studies; D005260:Female; D005431:Florida; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis